Indian pharmaceutical stocks fell up to 3% on Wednesday after US President Donald Trump unveiled a phased tariff plan of up to 200% on imported generic medicines, sending key drugmakers like Lupin, Cipla, and Sun Pharma into the red. The Nifty Pharma index dropped nearly 2% during early trading, as investors reacted to the prospect of steep long-term export duties on India’s generic drug sector.Markets React to Escalating US Duty PlanShares of top Indian drugmakers experienced across-the-board selling as markets digested President Trump’s latest trade policy shift targeting imported healthcare products. The Nifty Pharma index plunged over 1.7%, emerging as one of the hardest-hit sectoral indices of the trading session.Early Trading Loss SummaryStock / IndexPerformanceKey Intraday PriceNifty Pharma Index▼ 1.73%~25,639.70Lupin Ltd.▼ 2.50%₹2,437.70Cipla Ltd.▼ 2.06%₹1,403.00Sun Pharma▼ 1.28%₹1,936.95Aurobindo Pharma▼ 3.13%₹1,531.00Context: The United States represents more than one-third of total Indian pharmaceutical exports, making US-focused generic suppliers particularly sensitive to sudden trade policy modifications.What the Proposed Tariff Structure EntailsIn a public announcement, US President Donald Trump detailed a structured roadmap aimed at reshoring pharmaceutical manufacturing to American soil. Under the proposed policy framework:Two-Year Grace Period: Generic drug imports will continue to face a 0% tariff.Phase-One Escalation: A 100% duty will take effect for one year following the grace period.Phase-Two Escalation: Tariffs will increase further to 200% on companies that fail to establish US-based manufacturing infrastructure.Patented, innovative, and branded therapies remain excluded from the generic tariff framework.Analyst Perspective: Near-Term Jitters vs. Long-Term RealitiesDespite the initial market sell-off, institutional analysts suggest the real economic impact on Indian generic drugmakers may be less severe than price reactions indicate.Significant Cost Advantages: India-based manufacturing remains 40% to 60% cheaper than domestic US production. Even under tariff pressures, US buyers rely heavily on foreign supplies, as over 90% of US generic prescriptions are currently imported.Long Lead Times: Building, inspecting, and securing regulatory approvals for new US manufacturing plants takes anywhere from 3 to 4 years, creating operational hurdles for rapid reshoring efforts.Mitigating Factors: Major producers like Sun Pharma, Dr. Reddy’s, and Cipla already operate US-based subsidiaries or maintain diversified portfolios in complex generics and specialty drugs, helping insulate their revenue bases from basic generic tariffs.Also Read :- ABSL AMC Q1 Results 2026: Net Profit Rises 12% YoY to ₹310 Crore, AUM Reaches ₹10.7 Lakh Crore
